Keytruda®(pembrolizumab) – Expanded indication
October 13, 2021 - Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test.
Top